Table 2.

Univariate and multivariate analyses of risk factors for overall and recurrence-free survival following hepatic resection of intrahepatic cholangiocarcinoma.

Factors	Overall survival				Recurrence-free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age (≥ 69)	2.05 (0.96–4.37)	0.0634			1.37 (0.71–2.63)	0.3417
Male	1.07 (0.49–2.36)	0.8652			1.12 (0.57–2.22)	0.7346
Albumin (< 4.1 g/dL)	2.03 (0.98–4.22)	0.0578			1.32 (0.70–2.50)	0.3926
CA19–9 (≥ 69.9 U/mL)	2.62 (1.18–5.79)	0.0174*	2.26 (0.97–5.31)	0.0602	2.32 (1.20–4.49)	0.0127*	2.15 (1.07–4.32)	0.0317*
Tumor size (≥ 6.0 cm)	2.69 (1.26–5.76)	0.0109*	1.53 (0.62–3.76)	0.3568	2.62 (1.34–5.09)	0.0046*	1.70 (0.82–3.49)	0.1509
Poor differentiation	1.09 (0.52–2.27)	0.8196			1.38 (0.72–2.65)	0.3286
Microvascular invasion ( +)	2.18 (0.97–4.86)	0.0583			2.65 (1.35–5.23)	0.0048*	2.57 (1.20–5.49)	0.0150*
Bile duct invasion ( +)	2.04 (0.94–4.39)	0.0698			1.29 (0.69–2.43)	0.4229
Intrahepatic metastasis ( +)	2.28 (1.09–4.78)	0.0289*	1.02 (0.42–2.46)	0.9652	2.60 (1.36–4.96)	0.0037*	1.06 (0.50–2.24)	0.8833
Lymph node metastasis ( +)	3.39 (1.56–7.35)	0.0020*	3.17 (1.42–7.09)	0.0050*	2.40 (1.19–4.87)	0.0151*	2.10 (1.00–4.41)	0.0496*
Histological liver cirrhosis ( +)	1.38 (0.48–4.01)	0.5488			1.17 (0.46–3.01)	0.7433
Insulin or insulin secretagogues ( +)	1.09 (0.46–2.55)	0.8500			0.85 (0.39–1.85)	0.6773
NASH ( +)	0.97 (0.37–2.56)	0.9543			0.67 (0.24–1.93)	0.4627
BMI ≥ 25.0 kg/m2	3.30 (1.56–6.98)	0.0018*	2.61 (1.12–6.07)	0.0261*	3.18 (1.68–6.00)	0.0004**	2.29 (1.15–4.54)	0.0182*

BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CI, confident interval; HR, hazard ratio; NASH, non-alcoholic steatohepatitis, *P < 0.05 and **P < 0.001.